Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Progenics selects small-molecule HCV drug candidate for clinical development
December 2008
SHARING OPTIONS:

SAN FRANCISCO—Biopharma Progenics Pharmaceuticals Inc. announced last month the selection of a proprietary small-molecule drug candidate, designated PRO 206, for clinical development as a treatment of hepatitis C virus (HCV) infection. PRO 206 is an orally available, viral-entry inhibitor designed to prevent HCV from entering and infecting healthy liver cells. Dr. Ira M. Jacobson, medical director of Cornell University's Center for the Study of Hepatitis C, says the development of PRO 206 "has the potential to transform treatment of this disease."

"Inhibiting viral entry is a proven approach for treating other viral diseases, and I look forward to seeing this strategy explored in HCV infection," Jacobson says. DDN


Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.